A5082440485- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Hematological disorders and diagnostics
- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Retinoids in leukemia and cellular processes
- DNA Repair Mechanisms
- RNA modifications and cancer
- Neutropenia and Cancer Infections
- Epigenetics and DNA Methylation
- Blood disorders and treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CAR-T cell therapy research
- Cancer-related gene regulation
- Lung Cancer Treatments and Mutations
- Histone Deacetylase Inhibitors Research
- Mesenchymal stem cell research
- Bone and Joint Diseases
- Peptidase Inhibition and Analysis
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
Southern Medical University
2025
Nanfang Hospital
2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2015-2024
Institute of Hematology & Blood Diseases Hospital
2015-2024
National Clinical Research
2020-2024
Ruijin Hospital
2024
First Affiliated Hospital of Anhui Medical University
2022-2024
Anhui Medical University
2022-2024
Shanghai Ninth People's Hospital
2024
Shanghai Jiao Tong University
2024
Some prospective studies showed that rabbit antithymocyte globulin was inferior to horse as first-line therapy for patients with severe aplastic anemia. We retrospectively analyzed the clinical outcome of 455 children anemia who received (n=297) or (n=158) combined cyclosporine between 1992 and 2010. The response rates were comparable groups at 3 months [46% (136/294) versus 42% (66/153), P=0.55] 6 [60% (178/292) 55% (87/143), P=1.0]. Using multivariate analysis, differences in preparations...
Previous studies have shown that gut microbiota can affect human immune system in many ways. Our aim was to investigate quantitative differences faecal bacterial compositions of childhood acute lymphoblastic leukemia (ALL) patients compared those healthy children, so as identify individual species are related the etiology ALL. We recruited 81 subjects, including 58 with ALL and 23 controls. Fecal samples were collected examined by 16S rRNA arrays bioinformatics analysis. Both Principal...
Abstract Venetoclax, a selective BCL2 inhibitor, is extensively utilized in clinical settings for the treatment of acute myeloid leukemia (AML). However, its efficacy often compromised by development drug resistance. Hence, identification potential venetoclax combination strategies imperative to overcome this acquired In study, we discovered that inhibition METTL3 can synergistically enhance anti-leukemic venetoclax, and capable overcoming resistance vivo experiments various models....
Abstract Purpose: Patient-tailored minimal residual disease (MRD) monitoring based on circulating tumor DNA (ctDNA) sequencing of leukemia-specific mutations enables early detection relapse for pre-emptive treatment, but its utilization in pediatric acute myelogenous leukemia (AML) is scarce. Thus, we aim to examine the role ctDNA as a prognostic biomarker response treatment AML. Experimental Design: A prospective longitudinal study with 50 children AML was launched, and sequential bone...
Background To determine the prognostic significance of detection minimal residual disease (MRD) in children with AML1/ETO AML, we compared results reverse-transcription polymerase chain reaction (RT-PCR) and quantitative (RQ-PCR). Procedure Between January 2006 February 2013, 70 patients (≤16 years age) AML were included our study. Bone marrow samples evaluated using by both RT-PCR RQ-PCR assays. transcripts normalized to 105 ABL copies. Results When treated fewer than four courses therapy,...
The combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested to be safe effective for adult acute promyelocytic leukaemia (APL). As 2010, the role cytarabine (Ara-C) in APL was controversial. aim this study test efficacy safety ATRA ATO paediatric patients. Also, we assessed whether Ara-C could omitted ATRA- based trials children.We performed a randomized controlled trial patients (≤14 years age) our hospital from May 2010 December 2016. All were assigned...
The prognosis of children with acute monocytic leukemia (AML-M5) remains unsatisfactory and the risk profile is still controversial. We aim to investigate prognostic value clinical cytogenetic features propose a new stratification in AML-M5 children. included 132 AML-M5. Overall survival (OS) progression-free (PFS) were documented. Cox regression was performed evaluate potential factors prognosis. 5-year-OS 46.0% (95% confidence intervals, 41.6%-50.4%) all patients. There significantly lower...
T-cell acute lymphoblastic leukemia (T-ALL) is a rare hematological malignancy with poor prognosis. The present study aims to identify the precise risk grouping of children T-ALL. We analyzed outcomes for 105 consecutive patients treated using Chinese Children's Cancer Group ALL-2015 (CCCG-ALL-2015) protocol registered Clinical Trial Registry (ChiCTR-IPR-14005706) between 2015 and 2020 in our center. Nine out 21 clinical biological indicators were selected new scoring system based on...
To explore the safety and efficacy of blinatumomab in treatment CD19 positive (CD19+) B-cell acute lymphoblastic leukemia (B-ALL) children. A retrospective analysis was conducted on clinical data pediatric B-ALL patients who received from Hematology & Blood Diseases Hospital Chinese Academy Medical Sciences August 2021 to October 2023. Based their disease status, were divided into refractory/relapsed(RR) group, minimal residual clearance (MC) chemotherapy intolerance (IC) group. Clinical...
T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) expresses on leukemic stem progenitor populations of non-M3 acute myeloid leukemia (AML) as well T lymphocytes. TIM-3 is thought to be involved in the self-renewal cells immune escape AML cells, however its correlation with prognosis still controversial worthy further investigation.we simultaneously assessed expression levels blasts lymphocytes bone marrow de novo patients using flow cytometry. The correlations between...
Background The aim of the study was to validate diagnostic role circulating tumor DNA (ctDNA) in genetics aberration on basis next-generation sequencing (NGS) pediatric acute myeloid leukemia (AML). Methods Bone marrow (BM) and peripheral blood (PB) were collected from 20 AML children at time initial diagnosis, a ctDNA sample isolated PB. Detection mutation performed ctDNA, BM, mononuclear cell (PBMC) by NGS based 185-gene panel. Results Among 185 genes sequenced platform, total 82 abnormal...
The preferred salvage treatment for children with relapsed/refractory acute myeloid leukemia (R/R-AML) remains unclear. combination of cladribine/Ara-C/granulocyte-colony stimulating factor and mitoxantrone (CLAG-M) shown promising results in adult R/R-AML. We aim to investigate the efficacy safety CLAG-M versus mitoxantrone/etoposide/cytarabine (MEC) or idarubicin/etoposide/cytarabine (IEC) R/R-AML children.Fifty-five were analyzed. overall response rate (ORR), survival (OS),...
Non-Down's syndrome acute megakaryocytic leukemia (non-DS-AMKL) is a subtype of childhood myeloid (AML), whose prognosis, prognostic factors and treatment recommendations have not yet to be defined in children. We conducted retrospective study with 65 newly diagnosed non-DS-AMKL children from August 2003 June 2020 investigate the clinical impact outcome. Among all patients, 47 them were treated at our center who received three different regimens due time point admission (CAMS-another,...
Neutropenic children with hematological diseases were associated higher morbidity of carbapenem-resistant enterobacteriaceae (CRE) blood-stream infection (BSI) or colonization. But it was still murky regarding clinical characteristics, antimicrobial susceptibility, and outcomes CRE-BSI in these patients. We aimed to identify the potential risk factors for subsequent bacteremia outcome caused by CRE-BSI.Between 2008 2020, 2,465 consecutive neutropenic enrolled. The incidence characteristics...
To establish a new digital polymerase chain reaction (dPCR) system for the detection of BCR-ABL fusion gene in patients with chronic myeloid leukemia (CML), and explore its analytical performance clinical applicability BCR-ABLp190/210/230.A dPCR detecting BCR-ABLp190/210/230 was successfully developed, sensitivity difference qPCR improvement drug side effects CML during reduction or withdrawal were compared.Among 176 samples, showed high consistency (82.39%), positive rate about 5 times...